VRDN Annual CFO
-$184.17 M
-$90.33 M-96.26%
31 December 2023
Summary:
As of January 23, 2025, VRDN annual cash flow from operations is -$184.17 million, with the most recent change of -$90.33 million (-96.26%) on December 31, 2023. During the last 3 years, it has fallen by -$154.39 million (-518.46%). VRDN annual CFO is now -15667.98% below its all-time high of -$1.17 million, reached on December 31, 2013.VRDN Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRDN Quarterly CFO
-$67.71 M
-$21.65 M-47.00%
30 September 2024
Summary:
As of January 23, 2025, VRDN quarterly cash flow from operations is -$67.71 million, with the most recent change of -$21.65 million (-47.00%) on September 30, 2024. Over the past year, it has dropped by -$28.72 million (-73.68%). VRDN quarterly CFO is now -79754.12% below its all-time high of $85.00 thousand, reached on March 31, 2014.VRDN Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRDN TTM CFO
-$196.99 M
-$28.72 M-17.07%
30 September 2024
Summary:
As of January 23, 2025, VRDN TTM cash flow from operations is -$196.99 million, with the most recent change of -$28.72 million (-17.07%) on September 30, 2024. Over the past year, it has dropped by -$16.77 million (-9.31%). VRDN TTM CFO is now -53472.75% below its all-time high of -$367.70 thousand, reached on March 31, 2013.VRDN TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
VRDN Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -96.3% | -73.7% | -9.3% |
| 3 y3 years | -518.5% | -73.7% | -9.3% |
| 5 y5 years | -586.1% | -73.7% | -9.3% |
VRDN Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -237.4% | at low | -309.5% | at low | -260.9% | at low |
| 5 y | 5-year | -518.5% | at low | -1228.9% | at low | -599.8% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | at low | <-9999.0% | at low |
Viridian Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$67.71 M(+47.0%) | -$196.99 M(+17.1%) |
| June 2024 | - | -$46.06 M(+1.8%) | -$168.26 M(+0.5%) |
| Mar 2024 | - | -$45.22 M(+19.0%) | -$167.42 M(-9.1%) |
| Dec 2023 | -$184.17 M(+96.3%) | -$38.00 M(-2.5%) | -$184.17 M(+2.2%) |
| Sept 2023 | - | -$38.98 M(-13.8%) | -$180.21 M(+11.3%) |
| June 2023 | - | -$45.21 M(-27.0%) | -$161.90 M(+20.1%) |
| Mar 2023 | - | -$61.97 M(+82.0%) | -$134.77 M(+43.6%) |
| Dec 2022 | -$93.84 M(+71.9%) | -$34.04 M(+64.7%) | -$93.84 M(+22.9%) |
| Sept 2022 | - | -$20.67 M(+14.3%) | -$76.33 M(+13.0%) |
| June 2022 | - | -$18.09 M(-14.0%) | -$67.54 M(+5.4%) |
| Mar 2022 | - | -$21.04 M(+27.3%) | -$64.08 M(+17.4%) |
| Dec 2021 | -$54.58 M(+83.3%) | -$16.54 M(+39.2%) | -$54.58 M(+15.0%) |
| Sept 2021 | - | -$11.88 M(-18.8%) | -$47.48 M(+16.7%) |
| June 2021 | - | -$14.63 M(+26.8%) | -$40.70 M(+23.9%) |
| Mar 2021 | - | -$11.54 M(+22.3%) | -$32.86 M(+10.3%) |
| Dec 2020 | -$29.78 M(-17.4%) | -$9.44 M(+85.2%) | -$29.78 M(+5.8%) |
| Sept 2020 | - | -$5.09 M(-25.0%) | -$28.15 M(-12.9%) |
| June 2020 | - | -$6.79 M(-19.7%) | -$32.32 M(-1.2%) |
| Mar 2020 | - | -$8.46 M(+8.4%) | -$32.71 M(-9.3%) |
| Dec 2019 | -$36.06 M(+34.3%) | -$7.81 M(-15.8%) | -$36.06 M(-1.0%) |
| Sept 2019 | - | -$9.27 M(+29.2%) | -$36.42 M(+7.3%) |
| June 2019 | - | -$7.17 M(-39.2%) | -$33.96 M(+8.5%) |
| Mar 2019 | - | -$11.81 M(+44.5%) | -$31.29 M(+16.6%) |
| Dec 2018 | -$26.84 M | -$8.18 M(+20.2%) | -$26.84 M(+3.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$6.80 M(+51.0%) | -$25.91 M(+4.6%) |
| June 2018 | - | -$4.51 M(-38.8%) | -$24.77 M(-9.4%) |
| Mar 2018 | - | -$7.36 M(+1.6%) | -$27.34 M(-2.9%) |
| Dec 2017 | -$28.17 M(+289.5%) | -$7.24 M(+27.9%) | -$28.17 M(+23.5%) |
| Sept 2017 | - | -$5.66 M(-20.0%) | -$22.80 M(+24.9%) |
| June 2017 | - | -$7.08 M(-13.5%) | -$18.26 M(+38.4%) |
| Mar 2017 | - | -$8.18 M(+336.0%) | -$13.19 M(+82.4%) |
| Dec 2016 | -$7.23 M(+4.8%) | -$1.88 M(+67.0%) | -$7.23 M(+8.7%) |
| Sept 2016 | - | -$1.12 M(-44.0%) | -$6.65 M(-15.1%) |
| June 2016 | - | -$2.01 M(-9.6%) | -$7.83 M(-2.2%) |
| Mar 2016 | - | -$2.22 M(+71.1%) | -$8.01 M(+16.1%) |
| Dec 2015 | -$6.90 M(+211.7%) | -$1.30 M(-43.6%) | -$6.90 M(+4.6%) |
| Sept 2015 | - | -$2.30 M(+5.4%) | -$6.60 M(+28.8%) |
| June 2015 | - | -$2.19 M(+97.1%) | -$5.12 M(+50.4%) |
| Mar 2015 | - | -$1.11 M(+11.2%) | -$3.41 M(+54.0%) |
| Dec 2014 | -$2.21 M(+89.5%) | -$997.00 K(+20.0%) | -$2.21 M(+40.6%) |
| Sept 2014 | - | -$831.00 K(+76.8%) | -$1.57 M(+51.5%) |
| June 2014 | - | -$470.00 K(-652.9%) | -$1.04 M(+45.2%) |
| Mar 2014 | - | $85.00 K(-123.8%) | -$715.40 K(-38.8%) |
| Dec 2013 | -$1.17 M(-81.2%) | -$357.80 K(+20.8%) | -$1.17 M(+44.2%) |
| Sept 2013 | - | -$296.20 K(+102.3%) | -$810.30 K(+57.6%) |
| June 2013 | - | -$146.40 K(-60.2%) | -$514.10 K(+39.8%) |
| Mar 2013 | - | -$367.70 K | -$367.70 K |
| Dec 2012 | -$6.22 M | - | - |
FAQ
- What is Viridian Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Viridian Therapeutics?
- What is Viridian Therapeutics annual CFO year-on-year change?
- What is Viridian Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Viridian Therapeutics?
- What is Viridian Therapeutics quarterly CFO year-on-year change?
- What is Viridian Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Viridian Therapeutics?
- What is Viridian Therapeutics TTM CFO year-on-year change?
What is Viridian Therapeutics annual cash flow from operations?
The current annual CFO of VRDN is -$184.17 M
What is the all time high annual CFO for Viridian Therapeutics?
Viridian Therapeutics all-time high annual cash flow from operations is -$1.17 M
What is Viridian Therapeutics annual CFO year-on-year change?
Over the past year, VRDN annual cash flow from operations has changed by -$90.33 M (-96.26%)
What is Viridian Therapeutics quarterly cash flow from operations?
The current quarterly CFO of VRDN is -$67.71 M
What is the all time high quarterly CFO for Viridian Therapeutics?
Viridian Therapeutics all-time high quarterly cash flow from operations is $85.00 K
What is Viridian Therapeutics quarterly CFO year-on-year change?
Over the past year, VRDN quarterly cash flow from operations has changed by -$28.72 M (-73.68%)
What is Viridian Therapeutics TTM cash flow from operations?
The current TTM CFO of VRDN is -$196.99 M
What is the all time high TTM CFO for Viridian Therapeutics?
Viridian Therapeutics all-time high TTM cash flow from operations is -$367.70 K
What is Viridian Therapeutics TTM CFO year-on-year change?
Over the past year, VRDN TTM cash flow from operations has changed by -$16.77 M (-9.31%)